Iovance Biotherapeutics Inc (NASDAQ: IOVA) on Friday, soared 1.71% from the previous trading day, before settling in for the closing price of $1.75. Within the past 52 weeks, IOVA’s price has moved between $1.64 and $12.51.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 2739.80%. The company achieved an average annual earnings per share of 12.11%. With a float of $271.58 million, this company’s outstanding shares have now reached $333.93 million.
Let’s determine the extent of company efficiency that accounts for 838 employees. In terms of profitability, gross margin is 19.2%, operating margin of -187.5%, and the pretax margin is -178.03%.
Iovance Biotherapeutics Inc (IOVA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Iovance Biotherapeutics Inc is 18.67%, while institutional ownership is 64.01%. The most recent insider transaction that took place on May 14 ’25, was worth 42,250. In this transaction Interim CEO & General Counsel of this company bought 25,000 shares at a rate of $1.69, taking the stock ownership to the 374,646 shares. Before that another transaction happened on Nov 12 ’24, when Company’s Director sold 50,000 for $10.06, making the entire transaction worth $503,000. This insider now owns 7,500 shares in total.
Iovance Biotherapeutics Inc (IOVA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 12.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 47.62% during the next five years compared to 4.17% growth over the previous five years of trading.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Trading Performance Indicators
Iovance Biotherapeutics Inc (IOVA) is currently performing well based on its current performance indicators. A quick ratio of 3.64 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.23, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -0.71 in one year’s time.
Technical Analysis of Iovance Biotherapeutics Inc (IOVA)
Looking closely at Iovance Biotherapeutics Inc (NASDAQ: IOVA), its last 5-days average volume was 11.42 million, which is a drop from its year-to-date volume of 11.64 million. As of the previous 9 days, the stock’s Stochastic %D was 32.98%. Additionally, its Average True Range was 0.25.
During the past 100 days, Iovance Biotherapeutics Inc’s (IOVA) raw stochastic average was set at 2.17%, which indicates a significant decrease from 7.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 258.39% in the past 14 days, which was higher than the 123.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.0078, while its 200-day Moving Average is $7.0029. However, in the short run, Iovance Biotherapeutics Inc’s stock first resistance to watch stands at $1.8233. Second resistance stands at $1.8667. The third major resistance level sits at $1.9433. If the price goes on to break the first support level at $1.7033, it is likely to go to the next support level at $1.6267. Should the price break the second support level, the third support level stands at $1.5833.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Key Stats
Market capitalization of the company is 594.40 million based on 333,934K outstanding shares. Right now, sales total 164,070 K and income totals -372,180 K. The company made 49,320 K in profit during its latest quarter, and -116,160 K in sales during its previous quarter.
